Masanori Murakami

Short-term canagliflozin treatment remodels the gut microbiota and plasma bile acids in high-fat diet-fed mice

The sodium–glucose cotransporter 2 inhibitor canagliflozin exerts rapid cardiovascular and renal protective effects; however, its underlying mechanisms remain incompletely understood. Considering the emerging role of gut microbiota as pivotal mediators of drug efficacy, this study aimed to elucidate the short-term...